Browse by author
Lookup NU author(s): Dr Christopher Jones,
Professor Ruth Plummer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.
Author(s): Jones C, Plummer ER
Publication type: Article
Publication status: Published
Journal: British Journal of Radiology
Issue: Supplement 1
ISSN (print): 0007-1285
ISSN (electronic): 1748-880X
Publisher: British Institute of Radiology
Altmetrics provided by Altmetric